Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AbCellera Biologics ( (ABCL) ) has issued an announcement.
On November 10, 2025, AbCellera Biologics announced the appointment of Dr. Stephen Quake to its Board of Directors, enhancing the company’s commitment to scientific excellence. Dr. Quake, a renowned scientist and entrepreneur, brings extensive expertise in fields such as genomics and molecular diagnostics, aligning with AbCellera’s strategic goals. Concurrently, Andrew Lo resigned from the board, having contributed significantly to the company’s business and strategy since 2021.
The most recent analyst rating on (ABCL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.
Spark’s Take on ABCL Stock
According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.
AbCellera Biologics faces significant financial challenges, with negative profit margins and cash flow issues being the most impactful factors. Technical analysis indicates bearish momentum, and valuation metrics suggest the stock is overvalued. The earnings call provides some positive insights, particularly regarding liquidity and strategic transitions, but these are overshadowed by financial pressures.
To see Spark’s full report on ABCL stock, click here.
More about AbCellera Biologics
AbCellera Biologics Inc. is a clinical-stage biotechnology company that focuses on discovering and developing antibody-based medicines in the fields of endocrinology, women’s health, immunology, and oncology.
Average Trading Volume: 5,136,153
Technical Sentiment Signal: Sell
Current Market Cap: $1.21B
For a thorough assessment of ABCL stock, go to TipRanks’ Stock Analysis page.